Last Updated on October 6, 2024 by The Health Master
New Delhi: Drug major Sun Pharmaceutical Industries is recalling pre-filled syringes of a drug, used to treat infertility in women, in the US market due to a manufacturing issue, according to the US health regulator.
In its latest Enforcement Report, the US Food and Drug Administration (USFDA) noted that the Mumbai-based drug major is recalling 24,194 prefilled syringes of Fyremadel (ganirelix acetate) injection.
The company is recalling the affected lot due to the presence of particulate matter, the USFDA said. “A piece of glass was found in a prefilled syringe,” it added.
The product was manufactured by Sun Pharma and distributed in the US market by New Jersey-based Ferring Pharmaceuticals Inc. The company initiated the countrywide (US) recall on April 19 this year, USFDA stated.
The New Jersey-based Sun Pharmaceutical Inc, a unit of the company, has already announced the recall of 16,450 vials of Norepinephrine Bitartrate Injection for “failed impurities/degradation specifications”.
As per the USFDA, the drugmaker is also voluntarily recalling over 34,000 bottles of a generic medication, used to treat high blood pressure, in the US market due to failed dissolution testing.
The Indian pharmaceutical industry is the world’s third-largest by volume and 14th-largest in terms of value. India exported pharmaceuticals worth Rs 1,75,040 crore in the financial year 2021-22, including bulk drugs/ drug intermediates.
Drug recall: Thyronorm tablets recalled due to this reason
Drug recall: Sun Pharma, Hetero recall these drugs
Drug recall: 50,000 contaminated eye drops recalled
Drug recall: 55,000 bottles of Colchicine tablets due to this reason
Drug recall: Brimonidine Tartrate Ophthalmic Solution recalled due to this reason
Drug recall: 4,000 bottles of Tacrolimus Capsules recalled due to this reason
Lupin acquires this French Pharma company
NABL accredits more Laboratories with a total number of 8,386 Laboratories
USFDA gives approval for this first RSV Vaccine
National Medical Devices Policy 2023: Salient Features
Nitrosamine content high in some drugs
IPC invites laboratories to join Testing Programme for quality assurance
All Blood Centres / Banks to have NAT-PCR test by 2025
Moving towards zero counterfeiting to ease traceability and authentication
Drug alert: 48 out of 1497 samples declared as NSQ in March 2023
Wet Granulation vs Dry Granulation: Understanding the Key Differences
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
